Transplantation in highly HLA-sensitized patients: challenges and solutions

References

• Evans RW, Manninen DL, Garrison LP Jr, et al. The quality of life of patients with end-stage renal disease. N Engl J Med. 1985;312:553–559.
   PubMed Web of Science ®Google Scholar
• Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993;270:1339–1343.
   PubMed Web of Science ®Google Scholar
• The 2012 Annual Data Report [webpage on the Internet]. Minneapolis: US Department of Health & Human Services, Scientifc Registry of Transplant Recipients. Available from: http://srtr.transplant.hrsa.gov/annual_reports/2012. Accessed September 4, 2014.
   Google Scholar
• Kissmeyer-Nielsen F, Olsen S, Peterson VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet. 1966;2:662–665.
   PubMed Web of Science ®Google Scholar
• Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280:735–739.
   PubMed Web of Science ®Google Scholar
• Platt JL. Antibodies in transplantation. Discov Med. 2010;10:125–133.
   PubMed Web of Science ®Google Scholar
• Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation. 2002;74:1192–1194.
   PubMed Web of Science ®Google Scholar
• Taube D, Williams D, Cameron J. Renal transplantation after removal and prevention of resynthesis of HLA antibodies. Lancet. 1984;1:824–828.
   PubMed Web of Science ®Google Scholar
• Hodge EE, Klingman LL, Koo AP, et al. Pretransplant removal of anti-HLA antibodies by plasmapheresis and continued suppression on cyclosporine-based therapy after heart-kidney transplant. Transplant Proc. 1994;26:2750–2751.
   Web of Science ®Google Scholar
• Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 2008;29:608–615.
   PubMed Web of Science ®Google Scholar
• Hartnug H-P. Advances in the understanding of the mechanisms of IVIG. J Neurol. 2008;255:3–6.
   Web of Science ®Google Scholar
• Basta M. Ambivalent effect of immunoglobulin on the complement system: activation versus inhibition. Mol Immunol. 2008;45:4073–4079.
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into crossmatch positive recipients. Transplantation. 2000;70:887–895.
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011;365:318–326.
   PubMed Web of Science ®Google Scholar
• Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation. 2010;89:1095–1102.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIG IG02 trial. J Am Soc Nephrol. 2004;15:3256–3262.
   PubMed Web of Science ®Google Scholar
• Peng A, Vo A, Villicana R, et al. Long-term graft and patient outcomes in highly HLA-sensitized deceased donor kidney transplant recipients desensitized with high dose IVIG. Am J Transplant. 2008;8:303.
   Google Scholar
• Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006;6:346–351.
   PubMed Web of Science ®Google Scholar
• Marfo K, Ling M, Bao Y, et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation. 2012;94:345–351.
   PubMed Web of Science ®Google Scholar
• Lobashevsky AL, Higgins NG, Rosner KM, Mujtaba MA, Goggins WC, Taber TE. Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab. Transplantation. 2013;96:182–190.
   Web of Science ®Google Scholar
• Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359:242–251.
   PubMed Web of Science ®Google Scholar
• Vo AA, Petrozzino J, Yeung K, et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation. 2013;95:1–7.
   Web of Science ®Google Scholar
• Zachary AA, Montgomery RA, Leffel MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol. 2005;66:364–370.
   PubMed Web of Science ®Google Scholar
• Cecka JM, Zhang Q, Reed EF. Preformed cytotoxic antibodies in potential allograft recipients: recent data. Hum Immunol. 2005;66:343–349.
   Web of Science ®Google Scholar
• Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation. 2008;86:820–825.
   PubMed Web of Science ®Google Scholar
• Yabu JM, Higgins JP, Chen G, et al. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation. 2011;91:342–347.
   PubMed Web of Science ®Google Scholar
• US Renal Data System. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD, USA: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008. Available from: http://www.usrds.org/atlas08.aspx. Accessed August 20, 2014.
   Google Scholar
• Shehata N, Palda VA, Meyer RM, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev. 2010;24 Suppl 1:S7–S27.
   Google Scholar
• Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant. 2006;6:459–466.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Toyoda M, Kahwaji J, et al. Intravenous immunoglobulin (IVIG) a modular of immunity and inflammation with applications in solid organ transplantation. In: Kaplan B, Burkhart GJ, Lakkis FG, editors. Immunotherapy in Transplantation: Principles and Practice. Oxford, UK: Wiley-Blackwell; 2012.
   Google Scholar
• Gabardi S, Townsend K, Martin ST, Chandraker A. Evaluating the impact of pre-transplant desensitization utilizing a plasmapheresis and low-dose intravenous immunoglobulin protocol on BK viremia in renal transplant recipients. Transpl Infect Dis. 2013;15:361–368.
   Web of Science ®Google Scholar
• Kahwaji J, Sinha A, Toyoda M, et al. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol. 2011;6:2894–2900.
   Web of Science ®Google Scholar
• Barbosa D, Kahwaji J, Puliyanda D, et al. Polyomavirus BK viremia in kidney transplant recipients after desensitization with IVIG and rituximab. Transplantation. November 21, 2013. [Epub ahead of print.]
   Google Scholar
• Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients – where do we stand today? Am J Transplant. 2008;8:2192–2198.
   PubMed Web of Science ®Google Scholar
• Kaplan B, Gngemi A, Thielke J, Oberholzer J, Sankary H, Benedetti E. Successful rescue of refractory, severe antibody-mediated rejection with splenectomy. Transplantation. 2007;83:99–100.
   PubMed Web of Science ®Google Scholar
• Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody-mediated rejection. Am J Transplant. 2007;7:842–846.
   PubMed Web of Science ®Google Scholar
• Cecka JM, Kucheryavaya AY, Reinsmoen NL, Leffell MS. Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant. 2011;11:719–724.
   Web of Science ®Google Scholar
• Israni AK, Salkowski N, Gustafson S, et al. New national allocation policy for deceased donor kidneys in the United States and possible effect on patient outcomes. J Am Soc Nephrol. 2014;25:1842–1848.
   PubMed Web of Science ®Google Scholar
• Locke JE, Gentry SE, Simpkins CE, et al. Combining kidney paired donation, desensitization, and non-directed donors to transplant multiple highly sensitized patients. Am J Transplant. 2006;6:808.
   Google Scholar
• Yabu JM, Pando MJ, Busque S, Melcher ML. Desensitization combined with paired exchange leads to successful transplantation in highly sensitized kidney transplant recipients: strategy and report of five cases. Transplant Proc. 2013;45:82–87.
   Web of Science ®Google Scholar
• Vo AA, Wechsler EA, Wang J, et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant. 2008;8:144–149.
   PubMed Web of Science ®Google Scholar
• Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86:1754–1761.
   PubMed Web of Science ®Google Scholar
• Wu G, Chai N, Kim I, Klein AS, Jordan SC. Monoclonal anti-interleukin 6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization. Transpl Immunol. 2013;28:138–143.
   PubMed Web of Science ®Google Scholar
• Kim I, Wu G, Chia N, et al. Anti-IL-6 receptor antibody attenuates recall antibody responses in a mouse model of allosensitization. Transplantation. In press 2014.
   Google Scholar
• Chan A, Carter P. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10:301–316.
   PubMed Web of Science ®Google Scholar
• Mel H, Schmidt S, Dorner R. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther. 2012;14 Suppl 5:S1.
   Google Scholar